Loading clinical trials...
Loading clinical trials...
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial
Conditions
Interventions
Azacitidine
Bone Marrow Aspiration and Biopsy
+5 more
Start Date
July 1, 2026
Primary Completion Date
August 31, 2026
Completion Date
August 31, 2026
Last Updated
April 13, 2026
NCT05564390
NCT07320235
NCT06782542
NCT07295951
NCT07523555
NCT06284486
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions